Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals International (NASDAQ: KNSA) reported fourth-quarter and full-year 2025 results highlighting continued growth for ARCALYST in recurrent pericarditis, a return to profitability, and progress across its clinical pipeline, including its ongoing KPL-387 program and plans to enter the clinic with KPL-1161. ARCALYST revenue growth and 2026 guidance CEO Sanj K. Patel said ARCALYST revenue continued

LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time.

Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to a loss of $0.12 per share a year ago.

– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by the end of 2026 – – Cash balance increased by $170.4 million in 2025 to $414.1 million –       – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) --  – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported fourth quarter and full year 2025 financial results and recent portfolio execution. “Kiniksa continued to drive significant advancements across its commercial and clinical portfolio in 2025.

LONDON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 24, 2026 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and recent portfolio execution.

Kiniksa Pharmaceuticals International, plc (KNSA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance of $900–$920 million, approaching blockbuster status and supporting self-funding operations. Pipeline evolution with KPL-387 aims to improve adherence, capture full economics, and expand the addressable market, with Phase 2 data in H2 2026 as a key catalyst.

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy

Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by year end – – Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) –

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) CFO Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $41.89, for a total value of $502,680.00. Following the completion of the sale, the chief financial officer

LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

Voya Investment Management LLC decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 60.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,865 shares of the company's stock after selling 12,191 shares during the quarter. Voya

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $43.73 and last traded at $42.7640, with a volume of 103178 shares. The stock had previously closed at $42.00. Analyst Ratings Changes Several research firms recently weighed in

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) Director Barry Quart sold 20,129 shares of the firm's stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.51, for a total transaction of $835,554.79. Following the sale, the director directly owned 12,546 shares of the company's stock,